JTJan Taprogge

Jan Taprogge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jan Taprogge has a total of 727 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Trials in Molecular Radiotherapy: An Overview of the Landscape

    by N. Varmenot, K. Sjögreen Gleisner, J. Taprogge, G.D. Flux

  • Open Access

    Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer

    by Jan Taprogge, Iain Murray, Hannah Sharman, Paul Gape, Francesca Leek, Carla Abreu, Lenka Vávrová, Kate Newbold, Kee H Wong, Markus Luster, et al.

    Objective: Serum thyroglobulin measurements are used in the long-term management of patients with differentiated thyroid cancer following thyroidectomy and radioiodine therapy. The use of predictive biomarkers, such as post-operative stimulated thyroglobulin levels and absorbed dose, may help to identify patients at risk of disease recurrence or an unsuccessful initial treatment. Methods: Differentiated thyroid cancer patients treated with 1.1 or 3.7 GBq of radioiodine using recombinant human thyrotropin stimulation or thyroid hormone withdrawal were recruited into observational clinical studies in France, Germany and the UK with aligned study endpoints (MEDIRAD). The maximum absorbed dose to the thyroid remnant was determined and compared to post-operative stimulated thyroglobulin with respect to its ability to predict ablation success. Radioiodine therapy success was defined as unstimulated or stimulated thyroglobulin level of <0.2 or <1.0 ng/mL 9–12 months post-radioiodine. Results: Ninety-four patients had follow-up data and negative antithyroglobulin antibody tests. Seventy-eight patients (83%) were deemed excellent biochemical responders. Post-operative thyroglobulin and maximum absorbed dose predicted ablation success with receiver operating characteristic area under the curves of 0.83 ± 0.05 (P < 0.001) and 0.64 ± 0.08 (P = 0.12). A dose–response relationship between maximum absorbed dose and ablation success was found for patients with a post-operative stimulated thyroglobulin of ≥1 ng/mL. Conclusions: Predictions of ablation success using post-operative stimulated thyroglobulin or the absorbed dose to the thyroid remnant could inform personalisation of management of differentiated thyroid cancer and identify patients where further treatments or more intensive follow-up are required. Patients with a post-operative stimulated Tg of <1 ng/mL likely do not benefit from radioiodine.


  • First β -delayed γ -ray spectroscopy of Nb109 : Single-quasiparticle states with prolate shape in Mo109

    by S. Bae, T. Sumikama, P. M. Walker, J. G. Li, F. R. Xu, S. Choi, J. Ha, F. Browne, A. M. Bruce, I. Nishizuka, et al.

    The $\ensuremath{\beta}$-delayed $\ensuremath{\gamma}$-ray spectroscopy of $^{109}\mathrm{Nb}$ was performed to investigate the structure of $^{109}\mathrm{Mo}$ for the first time at the RIBF, Japan. Over one hundred transitions were assigned to $^{109}\mathrm{Mo}$, of these two were from the known isomeric state, and a new 33.1 keV excited state below the isomeric state was identified. The multipolarities of the transitions depopulating the isomeric state were restricted considering the internal conversion coefficients and empirically recommended upper limits of transition strengths. The intrinsic gyromagnetic ratio of the isomeric-state band was extracted, and the rotational band of the ground state was identified. The configurations of the ground and isomeric states in $^{109}\mathrm{Mo}$ were assigned to the $\ensuremath{\nu}1/{2}^{+}[411]$ and $\ensuremath{\nu}5/{2}^{+}[413]$ orbitals, respectively, with prolate shape. From the $logft$ analysis, the ground state in $^{109}\mathrm{Nb}$ and a new excited state in $^{109}\mathrm{Mo}$ with a small $logft$ value were assigned to the $\ensuremath{\pi}5/{2}^{+}[422]$ and $\ensuremath{\nu}5/{2}^{+}[402]$ orbitals, respectively. The assignments were supported by potential energy surface calculations using the configuration-constrained method with a triaxially deformed Woods-Saxon potential. Although the $\ensuremath{\nu}1/{2}^{+}[411]$ orbital was successfully predicted as the ground state, the order of quasiparticle configurations for excited states was not reproduced. The neutron emission probability in $^{109}\mathrm{Nb}$ $\ensuremath{\beta}$-decay was evaluated to be $27(11)%$ utilizing the $\ensuremath{\beta}$-delayed $\ensuremath{\gamma}$ rays of $^{109}\mathrm{Tc}$ and $^{108}\mathrm{Mo}$.


  • Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy

    by Jonathan Wadsley, Gemma Ainsworth, Amy Beth Coulson, Kate Garcez, Laura Moss, Kate Newbold, Kate Farnell, Jayne Swain, Helen Howard, Matthew Beasley, et al.


  • Open Access

    Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project

    by Jan Taprogge, Alex Vergara-Gil, Francesca Leek, Carla Abreu, Lenka Vávrová, Lily Carnegie-Peake, Sarah Schumann, Uta Eberlein, Michael Lassmann, Tino Schurrat, et al.

    Purpose: Dosimetry is rarely performed for the treatment of differentiated thyroid cancer patients with Na[131I]I (radioiodine), and information regarding absorbed doses delivered is limited. Collection of dosimetry data in a multi-centre setting requires standardised quantitative imaging and dosimetry. A multi-national, multi-centre clinical study was performed to assess absorbed doses delivered to normal organs for differentiated thyroid cancer patients treated with Na[131I]I. Methods: Patients were enrolled in four centres and administered fixed activities of 1.1 or 3.7 GBq of Na[131I]I using rhTSH stimulation or under thyroid hormone withdrawal according to local protocols. Patients were imaged using SPECT(/CT) at variable imaging time-points following standardised acquisition and reconstruction protocols. Whole-body retention data were collected. Dosimetry for normal organs was performed at two dosimetry centres and results collated. Results: One hundred and five patients were recruited. Median absorbed doses per unit administered activity of 0.44, 0.14, 0.05 and 0.16 mGy/MBq were determined for the salivary glands of patients treated at centre 1, 2, 3 and 4, respectively. Median whole-body absorbed doses for 1.1 and 3.7 GBq were 0.05 Gy and 0.16 Gy, respectively. Median whole-body absorbed doses per unit administered activity of 0.04, 0.05, 0.04 and 0.04 mGy/MBq were calculated for centre 1, 2, 3 and 4, respectively. Conclusions: A wide range of normal organ doses were observed for differentiated thyroid cancer patients treated with Na[131I]I, highlighting the necessity for individualised dosimetry. The results show that data may be collated from multiple centres if minimum standards for the acquisition and dosimetry protocols can be achieved.


  • Open Access

    Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

    by Jan Taprogge, Carla Abreu, Lenka Vávrová, Lily Carnegie-Peake, Dominic Rushforth, Paul Gape, Jonathan Gear, Iain Murray, Kee H. Wong, Kate Newbold, et al.

    Introduction: The optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.Materials and Methods: The INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.Results: We report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.Discussion: The preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.


  • Open Access

    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer

    by Jan Taprogge, Carla Abreu, Siraj Yusuf, Gemma Ainsworth, Rachel H. Phillip, Jonathan I. Gear, Rebecca Gregory, Francesca Leek, Iain Murray, Amy B. Coulson, et al.

    Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed. Methods: We performed a multicenter clinical trial to investigate the role of selumetinib, which modulates the expression of the sodium iodide symporter, and hence iodine uptake, in the treatment of RAI-refractory DTC. The iodine uptake before and after selumetinib was quantified to assess the effect of selumetinib. The range of absorbed doses delivered to metastatic disease was calculated from pre- and posttherapy imaging, and the predictive accuracy of a theranostic approach to enable personalized treatment planning was investigated. Results: Significant inter- and intrapatient variability was observed with respect to the uptake of RAI and the effect of selumetinib. The absorbed doses delivered to metastatic lesions ranged from less than 1 Gy to 1,170 Gy. A strong positive correlation was found between the absorbed doses predicted from pretherapy imaging and those measured after therapy (r = 0.93, P < 0.001). Conclusion: The variation in outcomes from RAI therapy of DTC may be explained, among other factors, by the range of absorbed doses delivered. The ability to assess the effect of treatments that modulate RAI uptake, and to estimate the absorbed doses at therapy, introduces the potential for patient stratification using a theranostic approach. Patient-specific absorbed dose planning might be the key to more successful treatment of advanced DTC. Visual Abstract


  • Radioiodine Dosimetric Approaches: Current Concepts and Future Directions

    by Jan Taprogge, Glenn Flux, Kate Garcez, Matthew Beasley, Jonathan Wadsley


  • Open Access

    Quantification and dosimetry of small volumes including associated uncertainty estimation

    by Lily Carnegie-Peake, Jan Taprogge, Iain Murray, Glenn D. Flux, Jonathan Gear

    Background: Accurate quantification of radioactivity in a source of interest relies on accurate registration between SPECT and anatomical images, and appropriate correction of partial volume effects (PVEs). For small volumes, exact registration between the two imaging modalities and recovery factors used to correct for PVE are unreliable. There is currently no guidance relating to quantification or the associated uncertainty estimation for small volumes. Material and methods: A method for quantification of small sources of interest is proposed, which uses multiple oversized volumes of interest. The method was applied to three Na[131I]I activity distributions where a Na[131I]I capsule was situated within a cylindrical phantom containing either zero background, uniform background or non-uniform background and to a scenario with small lesions placed in an anthropomorphic phantom. The Na[131I]I capsule and lesions were quantified using the proposed method and compared with measurements made using two alternative quantification methods. The proposed method was also applied to assess the absorbed dose delivered to a bone metastasis following [131I]mIBG therapy for neuroblastoma including the associated uncertainty estimation. Results: The method is accurate across a range of activities and in varied radioactivity distributions. Median percentage errors using the proposed method in no background, uniform backgrounds and non-uniform backgrounds were − 0.4%, − 0.3% and 1.7% with median associated uncertainties of 1.4%, 1.4% and 1.6%, respectively. The technique is more accurate and robust when compared to currently available alternative methods. Conclusions: The proposed method provides a reliable and accurate method for quantification of sources of interest, which are less than three times the spatial resolution of the imaging system. The method may be of use in absorbed dose calculation in cases of bone metastasis, lung metastasis or thyroid remnants.